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Objectives This study sought to evaluate the incidence, predictive factors, and prognostic value of new-onset atrial fibrilla-
tion (NOAF) following transcatheter aortic valve implantation (TAVI).
Background Very few data exist on the occurrence of NOAF following TAVI.
Methods A total of 138 consecutive patients with no prior history of atrial fibrillation (AF) underwent TAVI with a balloon-
expandable valve. Patients were on continuous electrocardiogram monitoring until hospital discharge, and NOAF
was defined as any episode of AF lasting 30 s. All clinical, echocardiographic, procedural, and follow-up data
were prospectively collected.
Results NOAF occurred in 44 patients (31.9%) at a median time of 48 h (interquartile range: 0 to 72 h) following TAVI. The
predictive factors of NOAF were left atrial (LA) size (odds ratio [OR]: 1.21 for each increase in 1 mm/m2, 95% confi-
dence interval [CI]: 1.09 to 1.34, p  0.0001) and transapical approach (OR: 4.08, 95% CI: 1.35 to 12.31, p 
0.019). At 30-day follow-up, NOAF was associated with a higher rate of stroke/systemic embolism (13.6% vs. 3.2%, p
 0.021, p  0.047 after adjustment for baseline differences between groups), with no differences in mortality rate
between groups (NOAF: 9.1%, no-NOAF: 6.4%, p  0.57). At a median follow-up of 12 months (interquartile range: 5
to 20 months), a total of 27 patients (19.6%) had died, with no differences between the NOAF (15.9%) and no-NOAF
(21.3%) groups, p  0.58. The cumulative rate of stroke and stroke/systemic embolism at follow-up were 13.6% and
15.9%, respectively, in the NOAF group versus 3.2% in the no-NOAF group (p  0.039, adjusted p  0.037 for stroke;
p  0.020, adjusted p  0.023 for stroke/systemic embolism).
Conclusions NOAF occurred in about one-third of the patients with no prior history of AF undergoing TAVI and its incidence was
increased in patients with larger LA size and those undergoing transapical TAVI. NOAF was associated with a higher
rate of stroke/systemic embolism, but not a higher mortality, at 30 days and at 1-year follow-up. (J Am Coll Cardiol
2012;59:178–88) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.061Transcatheter aortic valve implantation (TAVI) has become
an alternative treatment for patients with severe symptom-
atic aortic stenosis considered to be at very high or prohib-
itive operative risk (1–10). New-onset atrial fibrillation
(NOAF) is a well-known complication of cardiovascular
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accepted September 20, 2011.interventions, and its occurrence has been associated with a
higher rate of periprocedural cerebrovascular events and
cardiac mortality (11,12). However, very few data exist on
the occurrence of NOAF following TAVI, and no studies to
date have evaluated the predictive factors of this complica-
tion during transcatheter valve procedures. The potential
See page 189
role of NOAF in the occurrence of cardioembolic events
following TAVI is also unknown. The occurrence of cere-
brovascular events is probably the most worrisome compli-
cation associated with TAVI, with an incidence of about 4%
(1–10), one of the highest ever reported in the field of interven-
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January 10, 2012:178–88 TAVI and Atrial Fibrillationtional cardiology. Although about one-third of cerebrovascular
events occur during the TAVI procedure, 50% of them occur
several days after TAVI (1), suggesting that mechanisms other
than those directly related to the procedure may be involved.
The objectives of this study were therefore to determine the
incidence and predictive factors of NOAF in patients with no
history of chronic/paroxysmal atrial fibrillation (AF) undergo-
ing TAVI, and to evaluate the prognostic value of NOAF
as a complication of TAVI, with special attention to
cardioembolic events.
Methods
Study population and TAVI procedures. Between May
2007 and May 2011, a total of 195 consecutive patients with
severe symptomatic aortic stenosis underwent TAVI with a
balloon-expandable valve (Edwards SAPIEN, SAPIEN
XT, Edwards Lifesciences, Irvine, California) at our insti-
tution. Of these, 57 patients with prior chronic or paroxys-
mal AF were excluded, leading to a final study population of
138 patients. Details about the TAVI procedure (trans-
femoral and transapical) have been extensively explained in
previous studies (3). Selection of transapical approach was
based on the following criteria: small diameter of the
iliofemoral arteries (8,7,6.5, and6 mm for the 24-,
22-, 19-, and 18-F sheaths, respectively), significant periph-
eral vascular disease, severe calcification or tortuosity of both
iliofemoral arteries, severely calcified or porcelain aorta, and
horizontal ascending aorta. Patients received full-dose hep-
arin (100 U/kg, adjusted for an activated clothing time
250 s) during the procedure, and aspirin (80 mg/day) 
clopidogrel (75 mg/day) were administered following the
procedure. All procedures were performed under a compas-
sionate clinical program approved by Health Canada (Ot-
tawa, Ontario, Canada), and all patients provided signed
informed consent for the procedures. Clinical, echocardio-
graphic, and procedural data were entered prospectively into
a dedicated database. Left atrial size was defined as the
anteroposterior diameter measured during systole in the
parasternal long-axis view by M-mode echocardiography
using the leading edge of the posterior aortic wall to the
leading edge of the posterior atrial wall. All periprocedural
complications were recorded and defined on the basis of the
Valve Aortic Research Consortium criteria (13). Cerebro-
vascular events were classified as transient ischemic attack
(TIA) or stroke, which in turn was also categorized in
accordance to the Modified Rankin Scale (MRS) as major
stroke if MRS 2 at 30 days, or minor stroke if MRS 2
at 30 days (13). All cerebrovascular events were evaluated by
a neurologist and confirmed through neuroimaging tech-
niques. Strokes were further classified as early/procedure, if
a new neurological deficit was immediately apparent upon
recovery from anesthesia or within 24 h of the procedure,
and late/post-procedure, defined as those occurring 24 h
after the intervention. Systemic embolism was defined as an
abrupt vascular insufficiency associated with clinical or radio- ological evidence of arterial occlu-
sion in the absence of other likely
mechanisms (e.g., trauma, athero-
sclerosis, or instrumentation).
NOAF definition. Patients were
on continuous electrocardiogram
monitoring until hospital dis-
charge, and NOAF was defined as
any episode of AF lasting longer
than 30 s (14,15). The timing and
duration of the NOAF episode
and the need for electrical or phar-
macological cardioversion were re-
corded. The duration of the
NOAF episode was classified as
follows:1 min, 1 min to 1 h, 1 to
2 h, 12 to 24 h, 24 to 48 h, or
48 h. NOAF was managed fol-
owing the criteria of the latest
eviewed guidelines of the American College of Cardiology/
merican Heart Association (15). Anticoagulation was
tarted, unless contraindicated, immediately after the diagnosis
f NOAF and continued for at least 1 month. In case of short
pisodes (12 h) of AF, the potential risks/benefits of antico-
gulation were evaluated in each patient, and the decision was
nally made by the physician responsible for the patient. In
atients with an epidural catheter for pain relief after transapi-
al TAVI, anticoagulation was delayed 24 h after the removal
f the catheter following the criteria of the American Associ-
tion of Regional Anesthesia and Pain Medicine (16). War-
arin was used as anticoagulant therapy in all cases, with the
bjective of an international normalized ratio between 2 and 3.
ntravenous heparin was administered until therapeutic anti-
oagulation levels were achieved.
ollow-up. The clinical follow-up was carried out through
linical visits or telephone contact and was available in 100% of
he study population. Cardiovascular events were defined
ollowing the Valve Aortic Research Consortium criteria (13).
he occurrence and timing of new episodes of AF was also
ecorded. Death at any time during the follow-up period was
ecorded and further classified as of cardiac or noncardiac
rigin.
tatistical analysis. Continuous variables are expressed as
ean  SD or median (25th to 75th interquartile range
IQR]), depending on variable distribution. Group compar-
sons were analyzed using Student t test or Wilcoxon rank
um test for continuous variables, and chi-square test or
isher exact test for categorical variables. The variables
ssociated with NOAF were determined by univariate
nalysis, and those variables with a p value 0.05 were
ntered in a logistic regression analysis to determine the
ndependent predictors of NOAF. The univariate normality
ssumptions were verified with the Shapiro-Wilk test. The
ultivariate normality assumptions were verified with the
hapiro-Wilk test after a Cholesky factorization. Receiver-
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
HR  hazard ratio
IQR  interquartile range
MRS  Modified Rankin
Score
NOAF  new-onset atrial
fibrillation
OR  odds ratio
ROC  receiver-operating
characteristic
TAVI  transcatheter aortic
valve implantation
TIA  transient ischemic
attackperating characteristic (ROC) curve analysis was per-
t
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TAVI and Atrial Fibrillation January 10, 2012:178–88formed to discriminate power of the atrial size for the
occurrence of NOAF. The maximum sum of sensitivity and
specificity was used as the criterion to identify an optimal
cutoff point in the ROC analysis. The association between
NOAF and clinical outcomes (i.e., cardioembolic events
and death) was analyzed with the use of univariate and
multivariate logistic regression (30-day outcomes) or Cox
proportional hazards (late outcomes) analyses. The multi-
variate models were adjusted for the baseline differences
Baseline Characteristics ofthe Study Population (N  138)Table 1 B sel ne Characteristics ofthe Study Population (N  138)
Baseline variables
Age, yrs 79 8
Male 54 (39.1)
BMI, kg/m2 27 5
Diabetes 52 (37.7)
Dyslipidemia 114 (82.6)
Hypertension 126 (91.3)
NYHA functional class
I–II 23 (16.7)
III–IV 115 (83.3)
Coronary artery disease 90 (65.2)
Previous myocardial infarction 48 (34.8)
Previous PCI 55 (39.9)
Prior coronary artery bypass grafting 52 (37.7)
Cerebrovascular disease 31 (22.5)
Peripheral vascular disease 53 (38.4)
COPD 39 (28.3)
Creatinine, mg/dl 1.18 (0.88–1.61)
eGFR 60 ml/min 89 (64.5)
Logistic EuroSCORE 21.7 15.7
STS-PROM score, % 7.4 4.8
CHADS2 score 3 (3–4)
Severely calcified or porcelain aorta 42 (30.4)
Frailty 24 (17.4)
Severe pulmonary hypertension 13 (9.4)
Echocardiographic variables
Mean aortic gradient, mm Hg 43 17
Aortic valve area, cm2 0.6 (0.5–0.7)
LVEF, % 55 14
LVEF 40 23 (16.7)
Severe mitral regurgitation 4 (2.9)
Left ventricular mass, g/m2 125.5 36.4
LVEDD, mm 46.9 7.9
Left atrial size, mm 44.7 8.0
Left atrial size, indexed, mm/m2 26.4 5.4
Systolic pulmonary pressure, mm Hg 43.5 11.9
Baseline treatment
Aspirin 120 (86.9)
Clopidogrel 11 (7.9)
Warfarin 1 (0.7)
ACE inhibitors/ARA2 80 (57.9)
Diuretics 102 (73.9)
Beta-blockers 70 (50.7)
Statins 116 (84.1)
Amiodarone 0
Continued in next column(p  0.05 in the univariate analysis) between the NOAF and no-NOAF groups. The variables included in the
models were prior coronary bypass grafting, severely calci-
fied or porcelain aorta, left atrial size, and transapical
approach. Late outcomes were also assessed by Kaplan-
Meier estimates and compared using the log-rank test. The
results were considered significant with p values 0.05. All
analyses were conducted using the statistical package SAS
version 9.2 (SAS Institute, Cary, North Carolina).
Results
The clinical, echocardiographic, and procedural characteristics
of the study population are shown in Table 1. Procedural
success and 30-day mortality rates were 93.5% and 7.3%,
respectively. Eight patients (5.8%) had a stroke following the
procedure, all of which were ischemic in etiology as evidenced
by neuroimaging techniques. One more patient without prior
significant peripheral artery disease who underwent transapical
TAVI suffered acute left lower limb ischemia 2 days after the
procedure secondary to an infrapopliteal arterial obstruction as
diagnosed by Doppler ultrasonography. The initial manage-
ment with anticoagulation therapy resolved the arterial occlu-
sion, and no further intervention was required, which corrob-
orated its thrombotic nature.
NOAF occurred in a total of 44 patients (31.9%) within
30 days following TAVI. The timing and duration of the
episodes of NOAF are shown in Figures 1 and 2, respec-
ively. NOAF occurred at a median time of 48 h (IQR: 0 to
2 h) following TAVI. Up to 40% of the NOAF episodes
ccurred either during (n  16, 36.3%) or within the 24 h
ollowing the procedure (n  2, 4.6%). A total of 10
rrhythmic episodes (22.7%) resolved spontaneously, lasting
ContinuedTable 1 Continued
Procedural variables and 30-day outcomes
Approach
Transfemoral 38 (27.5)
Transapical 100 (72.5)
Procedural success 129 (93.5)
Valve embolization 1 (0.7)
Need for a second valve 5 (3.6)
Need for hemodynamic support 4 (2.9)
Major vascular complications 13 (9.4)
Myocardial infarction 0
Cerebrovascular event
Transient ischemic attack 0
Stroke 8 (5.8)
Minor 3 (2.2)
Major 5 (3.6)
Fatal 0
Death 10 (7.3)
Values are mean  SD, n (%), or median (interquartile range).
ACE  angiotensin-converting enzyme; ARA2  angiotensin II receptor antagonist; BMI  body
mass index; COPD  chronic obstructive pulmonary disease; eGFR  estimated glomerular
filtration rate; LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular ejection
fraction; NYHA  New York Heart Association; PCI  percutaneous coronary intervention; STS-
PROM  Society of Thoracic Surgeons predicted risk of mortality.12 h in all cases, and 34 episodes (77.3%) required
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January 10, 2012:178–88 TAVI and Atrial Fibrillationpharmacological (intravenous amiodarone; n  19, 43.2%)
r electrical (n  15, 34.1%) cardioversion. The cardiover-
ion was effective in all but 1 patient, who remained in AF
t hospital discharge. Anticoagulation (with intravenous
eparin and warfarin) was initiated immediately after the
iagnosis of NOAF in 34 of the 44 patients (77.3%) with
OAF. Anticoagulation treatment was delayed 24 h in 3
atients with epidural catheters to allow the safe removal of
he catheter. In the other 7 patients, a decision to maintain
ntithrombotic treatment with aspirin and clopidogrel with-
ut anticoagulation was made due to the very short duration
f the NOAF episode (12 h in all of them) and an
stimated high risk of bleeding with the addition of anti-
oagulation therapy. The length of hospital stay for the
atients who experienced NOAF was 9 days (IQR: 7 to 14
ays), which was significantly longer than that of the rest of
he study population (6 days, IQR: 5 to 9 days, p 0.0004).
t hospital discharge, the antithrombotic treatment for the
4 patients who presented with NOAF was as follows:
spirin alone (n  2, 4.5%), aspirin  clopidogrel (n  6,
3.6%), warfarin alone (n  1, 2.3%), warfarin  aspirin
n  24, 54.5%), and warfarin  aspirin  clopidogrel (11
atients, 25.0%). A total of 14 patients (31.8%) and 20
atients (45.5%) were on amiodarone or beta-blockers,
espectively, at hospital discharge. Mean international nor-
alized ratio level at hospital discharge was 2.6  0.5 for
he 36 patients under warfarin therapy, with 3 and 6 patients
xhibiting international normalized ratio levels below 2 and
bove 3, respectively.
redictive factors of NOAF. Baseline and procedural
haracteristics of the patients grouped according to the
ccurrence of NOAF are shown in Table 2. In the multi-
ariate analysis, a larger atrial size (odds ratio [OR]: 1.21 for
ach increase in 1 mm/m2, 95% confidence interval [CI]:
1.09 to 1.34, p  0.0001) and transapical approach (OR:
4.08, 95% CI: 1.35 to 12.31, p  0.019) were the 2
independent predictors of NOAF following the procedure.
Figure 1 Timing of NOAF Following TAVI
Temporal distribution of the first episodes of atrial fibrillation with respect to
the transcatheter aortic valve implantation (TAVI) procedure in the 44 patients
with new-onset atrial fibrillation (NOAF).An atrial size 27 mm/m2 as measured by echocardiogra-phy was identified as the cutoff point with the best sensi-
tivity (67%) and specificity (61%) for the prediction of
NOAF following TAVI within 30 days, with an area under
the ROC curve of 0.71 (95% CI: 0.62 to 0.80, p  0.0001)
(Fig. 3). The incidence of NOAF in patients with an atrial
size27 mm/m2 undergoing TAVI by transapical approach
as 51% compared with 12% in patients with an atrial size
27 mm/m2 undergoing TAVI by transfemoral approach.
Follow-up. The median follow-up for the study population
was 12 months (IQR: 5 to 20 months). During the
follow-up period, a total of 7 patients with NOAF (15.9%)
had at least 1 more episode of AF compared with 2 patients
(2.1%) in the group with no-NOAF at 30 days (p  0.005).
The Kaplan-Meier curves at 1-year follow-up showing
freedom from new episodes of AF during the follow-up
period are shown in Figure 4. A total of 17 patients (12.3%)
died during the follow-up period: 4 (2.9%) from cardiac
causes and 13 (9.4%) from noncardiac causes.
Cerebrovascular events, systemic embolism, andNOAF. The
incidence of cerebrovascular events, systemic embolism, and
death following TAVI grouped according to the occurrence
of NOAF are shown in Table 3. The incidence of stroke at
0 days tended to be higher in the NOAF group (11.4%)
ompared with the no-NOAF group (3.2%, OR: 3.89, 95%
I: 0.89 to 17.08, p  0.056, p  0.068 after adjusting for
aseline differences between groups), and the incidence of
he combined endpoint of stroke and systemic embolism
as higher in the NOAF group compared with the no-
OAF group (13.6% vs. 3.2%, OR: 4.79, 95% CI: 1.14 to
0.15, p  0.021, p  0.047 after adjusting for baseline
ifferences between groups). During the follow-up period, 1
atient in the NOAF group had a stroke, and 1 patient in
he no-NOAF group presented with a TIA, 22 and 4
onths after the procedure, respectively. The cumulative
ncidence of stroke at follow-up was higher in the NOAF
roup compared with the no-NOAF group (13.6% vs.
.2%, hazard ratio [HR]: 4.32, 95% CI: 1.08 to 17.28, p 
.039, p  0.037 after adjusting for baseline differences
Figure 2 Duration of NOAF Episodes
Duration of the episodes of atrial fibrillation following TAVI.
NOAF  new-onset atrial fibrillation.
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TAVI and Atrial Fibrillation January 10, 2012:178–88Clinical and Procedural Characteristics of the PatientsAccording to the Occurrence of NOAFTable 2 Clinical and Procedu al Charact ristics of the PatientsAccording to the Occurrence of NOAF
NOAF
Variables
Yes
(n  44)
No
(n  94) p Value
Baseline variables
Age, yrs 79 9 79 8 0.81
Male 14 (31.8) 40 (42.6) 0.26
BMI, kg/m2 26 4 27 5 0.20
Diabetes 15 (34.1) 37 (39.4) 0.58
Dyslipidemia 37 (84.1) 77 (81.9) 0.63
Hypertension 41 (93.2) 85 (90.4) 0.75
Coronary artery disease 25 (56.8) 65 (69.1) 0.18
Previous myocardial infarction 14 (31.8) 34 (36.2) 0.70
Previous PCI 14 (31.8) 41 (43.6) 0.20
Prior coronary artery bypass grafting 11 (25.0) 41 (43.6) 0.039
Cerebrovascular disease 8 (18.2) 23 (24.5) 0.51
Peripheral vascular disease 16 (36.4) 37 (39.4) 0.85
COPD 11 (25.0) 28 (29.8) 0.69
Creatinine, mg/dl 1.18 (0.96–1.58) 1.18 (0.86–1.65) 0.61
eGFR 60 ml/min 31 (70.5) 58 (61.7) 0.35
Logistic EuroSCORE 20.3 19.5 22.3 13.6 0.06
STS score, % 6.8 5.0 7.6 4.6 0.12
CHADS2 score 3 (3–4) 3 (3–4) 0.40
Severely calcified or porcelain aorta 19 (43.2) 23 (24.4) 0.03
Frailty 7 (15.9) 17 (18.1) 0.81
Severe pulmonary hypertension 5 (11.4) 8 (8.5) 0.75
Echocardiographic variables
Mean aortic gradient, mm Hg 44.9 17.5 42.3 16.4 0.40
Aortic valve area, cm2 0.60 (0.50–0.70) 0.64 (0.50–0.76) 0.26
LVEF, % 57 13 53 16 0.21
LVEF 40 4 (9.1) 19 (20.2) 0.14
Severe mitral regurgitation 2 (4.5) 2 (2.1) 0.59
Left ventricular mass, g/m2 56.8 12.2 53.8 15.2 0.96
LVEDD, mm 45.7 7.0 47.4 8.2 0.25
Left atrial size, mm 49.7 9.5 42.5 6.0 0.0001
Left atrial size, indexed, mm/m2 29.3 6.5 25.0 4.3 0.0002
Systolic pulmonary pressure, mm Hg 42.4 15.2 43.9 10.3 0.58
Baseline treatment
Aspirin 37 (84.1) 83 (88.3) 0.59
Clopidogrel 2 (4.5) 9 (9.6) 0.70
Warfarin 0 1 (1.1) 1.00
ACE inhibitors/ARA2 24 (54.5) 56 (59.6) 0.59
Diuretics 31 (70.5) 71 (75.5) 0.54
Beta-blockers 22 (50.0) 48 (51.1) 1.00
Statins 37 (84.1) 79 (84.0) 1.00
Amiodarone 0 0 —
Procedural variables
Approach
Transfemoral 6 (13.6) 32 (34.0) 0.014
Transapical 38 (86.4) 62 (65.9)
Procedural success 42 (95.5) 87 (92.5) 0.72
Valve embolization 0 1 (1.1) 1.00
Need for a second valve 2 (4.5) 3 (3.2) 0.65
Need for hemodynamic support 2 (4.5) 2 (2.1) 0.59
Major vascular complications 2 (4.5) 11 (11.7) 0.23Values are mean  SD, n (%), or median (interquartile range).
NOAF  new-onset atrial fibrillation; other abbreviations as in Table 1.
183JACC Vol. 59, No. 2, 2012 Amat-Santos et al.
January 10, 2012:178–88 TAVI and Atrial Fibrillationbetween groups). The cumulative incidence of the compos-
ite of stroke or systemic embolism was also higher in the
NOAF group (15.9% vs. 3.2%; HR: 5.0, 95% CI: 1.29 to
Figure 3 ROC Curve Analysis for Atrial Size
Receiver-operating characteristic (ROC) curve showing the sensitivity and speci-
ficity of atrial size 27 mm/m2 for determining the occurrence of new-onset
atrial fibrillation following transcatheter aortic valve implantation.
Figure 4 New Episodes of AF During the Follow-Up Period
Kaplan-Meier survival curves at 1-year follow-up showing the percent of patients fr
(30 days after the transcatheter aortic valve implantation procedure), according19.35; p  0.020, p  0.023 after adjusting for baseline
differences between groups). The main individual charac-
teristics and the timing of the event in the 9 patients who
had a stroke and the patient who developed a systemic
embolism following the procedure are shown in Table 4. A
total of 4 strokes occurred early (24 h post-TAVI) and 5
late (24 h post-TAVI). One of the 4 early strokes (25%)
occurred in a patient with NOAF, whereas all 5 late strokes
occurred in patients with NOAF (100%, p  0.048 com-
pared with early strokes). Among the patients with NOAF,
the stroke/systemic embolism rate at 30 days in those
patients for whom anticoagulant therapy was not initiated
immediately after the diagnosis of NOAF was 40% com-
pared with 2.9% in those who received anticoagulant treat-
ment immediately after the diagnosis of NOAF (p 
0.008). Figure 5 shows the distribution of NOAF patients
according to the duration of the NOAF episode, anticoag-
ulant treatment upon the diagnosis of NOAF, and cardio-
embolic events. There were no differences between the
NOAF and no-NOAF groups regarding follow-up mortal-
ity (NOAF: 15.9%, no-NOAF: 21.3%, HR: 0.79, 95% CI:
0.33 to 1.86, p  0.58, p  0.56 after adjusting for baseline
differences) and the combined endpoint of death and stroke
(NOAF: 27.3%, no-NOAF: 24.5%, HR: 1.16, 95% CI:
0.58 to 2.35, p  0.67, p  0.76 after adjusting for baseline
differences). The Kaplan-Meier curves at 1-year follow-up
for freedom of death, stroke, cerebrovascular event (stroke
and TIA), and the combined endpoint of death and stroke
are shown in Figure 6.
ew episodes of atrial fibrillation (AF) during the follow-up period
occurrence of new-onset atrial fibrillation (NOAF) within 30 days.ee of n
to the
transi
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NOAF occurred in up to 31% of the patients with no prior
chronic/paroxysmal AF undergoing TAVI with a balloon-
expandable valve by transfemoral or transapical approach. A
larger atrial size and transapical approach were the predic-
tive factors of NOAF following TAVI. NOAF was associ-
ated with a higher rate of stroke or systemic embolism
acutely and at midterm follow-up, but there were no
differences in global and cardiac mortality between patients
30-Day and Late Cardioembolic Events and DeaAccording to th Occurrence of NOAFTable 3 30-Day and Lat Cardioembolic EveAccording to the Occurrence of NO
Variables
Yes
(n  44)
30-day outcomes
Cerebrovascular event 5 (11.4)
TIA 0
Stroke 5 (11.4)
Minor 2 (4.5)
Major 3 (6.8)
Fatal 0
Systemic embolism 1 (2.3)
Stroke or systemic embolism 6 (13.6)
Death 4 (9.1)
Death or stroke 9 (20.5)
Follow-up (30-day) outcomes
Months follow-up 12 (12–24)
Cerebrovascular event 1 (2.3)
TIA 0
Stroke 1 (2.3)
Minor 1 (2.3)
Major 0
Fatal 0
Systemic embolism 0
Stroke or systemic embolism 1 (2.3)
Death 3 (6.8)
Cardiac 1 (2.3)
Noncardiac 2 (4.5)
Death or stroke 3 (6.8)
Cumulative outcomes
Cerebrovascular event 6 (13.6)
TIA 0
Stroke 6 (13.6)
Minor 3 (6.8)
Major 3 (6.8)
Fatal 0
Systemic embolism 1 (2.3)
Stroke or systemic embolism 7 (15.9)
Death 7 (15.9)
Cardiac 5 (11.4)
Noncardiac 2 (4.5)
Death or stroke 12 (27.3)
Values are n (%) or median (25th to 75th interquartile range). *Values
for follow-up (30-day) outcomes and cumulative outcomes. †p Val
proportional hazards regression (HR).
CI  confidence interval; NOAF  new-onset atrial fibrillation; TIA with and without NOAF.Very few data exist on the occurrence of NOAF following
TAVI. In fact, NOAF has not been included as a potential
complication of TAVI in any of the recent large multicenter
TAVI registries (3–10). The PARTNER (Placement of
Aortic Transcatheter Valve) trial (high-risk cohort) in-
cluded 347 patients who underwent TAVI with a balloon-
expandable valve either by transfemoral or transapical ap-
proach (2). The incidence of NOAF within 30 days was
15% among the patients with no prior AF, which is about
one-half the incidence reported in the present study. Unlike
nd Death
No
(n  94) OR/HR (95% CI)* p Value
3 (3.2) 3.89 (0.89–17.08) 0.056
0 — —
3 (3.2) 3.89 (0.89–17.08) 0.056
1 (1.1) 4.54 (0.40–51.49) 0.18
2 (2.1) 3.45 (0.55–21.45) 0.16
0 — —
0 — —
3 (3.2) 4.79 (1.14–20.15) 0.021
6 (6.4) 1.47 (0.39–5.49) 0.57
9 (9.6) 2.43 (0.89–6.63) 0.077
12 (5–23) — 0.17
1 (1.1) — —
1 (1.1) — —
0 — —
0 — —
0 — —
0 — —
0 — —
0 — —
14 (14.9) 0.48 (0.14–1.67) 0.25
3 (3.2) 0.82 (0.08–7.97) 0.86
11 (11.7) 0.39 (0.09–1.79) 0.23
14 (14.9) 0.48 (0.14–1.67) 0.25
4 (4.3) 4.27 (1.07–17.09) 0.040
1 (1.1) — —
3 (3.2) 4.32 (1.08–17.28) 0.039
1 (1.1) 6.39 (0.66–61.42) 0.11
2 (2.1) 3.21 (0.54–19.23) 0.20
0 — —
0 — —
3 (3.2) 5.00 (1.29–19.35) 0.020
20 (21.3) 0.79 (0.33–1.86) 0.58
9 (9.6) 1.28 (0.43–3.82) 0.66
11 (11.7) 0.39 (0.086–1.79) 0.23
23 (24.5) 1.16 (0.58–2.35) 0.67
essed as odds ratios (OR) for 30-day outcomes and hazard ratios (HR)
rs to the significance of the logistic regression analysis (OR) or Cox
ent ischemic attack.thnts a
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January 10, 2012:178–88 TAVI and Atrial FibrillationPARTNER trial underwent the procedure by transfemoral
approach, and the rate of NOAF was close to the rate of
16% observed in our cohort of transfemoral approach
patients. Our patients also were continuously monitored
until hospital discharge, and NOAF was defined as any
episode of AF lasting 30 s (including those episodes
during the TAVI procedure), with up to 5% of the AF
episodes lasting 1 min and about one-third of them
lasting 1 h. It is unclear whether prior studies were
reporting such very short episodes of atrial arrhythmias, and
this might explain the higher NOAF rate observed in our
study. However, the 31% rate of NOAF observed in our
study population would have decreased to 21% if patients with
prior AF had not been excluded, and this incidence is still
lower than the 33% to 49% rate reported following valvular
cardiac surgery or the 36% to 63% rate reported following
combined valvular and coronary artery bypass surgery (11). To
the best of our knowledge, this is the first study evaluating the
timing and duration of NOAF following TAVI. Interestingly,
about one-third of the AF episodes occurred during the TAVI
procedure, and up to 45% of them occurred within the 24 h
following TAVI. Also, and in accordance with previous cardiac
surgery studies (11), the occurrence of NOAF was associated
with a prolongation of hospital stay (mean of 3 days), which in
turn would be associated with a significant increase in hospital
costs for the TAVI procedure.
Predictive factors of NOAF following TAVI. Previous
studies have shown an association between severe aortic
stenosis and atrial enlargement (17,18), but no prior data
were available for the subset of patients considered at very
high or prohibitive surgical risk. The mean atrial size in our
study population was larger than that observed in other
studies in the general population and in patients with
systemic hypertension (19,20). Aortic stenosis is associated
with diastolic dysfunction, which in turn might lead to a
dilation of the left atrium (17,18,21). This atrial enlarge-
ment has been recognized as a predictive factor of NOAF
following cardiac surgery as well as of AF recurrence in
patients with paroxysmal AF (22,23). Atrial dilation is
associated with fibrotic changes of the atrial wall and slow
atrial conduction, which might increase the vulnerability for
AF (24). The present study has shown that atrial enlarge-
ment is an independent predictor of NOAF in patients
undergoing TAVI, with an indexed atrial size of 27 mm/m2
exhibiting the best sensitivity and specificity for predicting
the occurrence of NOAF. The transapical approach was also
an independent predictor of NOAF following TAVI. Un-
like the transfemoral approach, the transapical approach
requires a left mini-thoracotomy and a direct puncture of
the left ventricular apex. It is well known from thoracic
surgery studies (excluding cardiac interventions) that thora-
cotomy is associated with NOAF in 10% to 20% of patients
(25,26). The ventilatory restriction and the hyperadrenergic
status generated by post-operative pain have been identified
as factors associated with NOAF following noncardiac
thoracic interventions (25,26). Particularly in the transapicalIn
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TAVI and Atrial Fibrillation January 10, 2012:178–88approach, direct myocardial injury secondary to the apex
puncture and surgical repair may also play a role in the
occurrence of NOAF (27). Several preventive strategies
such us amiodarone, beta-blockers, or angiotensin-
converting enzyme inhibitors/angiotensin II receptor antag-
onists have shown their efficacy in preventing NOAF in
systemic hypertension following cardiac surgery procedures
(21,28). Knowing the predictive factors of NOAF following
TAVI should allow us to select the patients at higher risk
for NOAF preventive studies in the setting of TAVI.
NOAF and cardioembolic events following TAVI. The
occurrence of cerebrovascular events has become the most
worrisome complication associated with TAVI. The stroke
rate of 5.8% at 30 days observed in the present study is
consistent with the 4% (0.6% to 5%) rate reported in
ecent multicenter registries (3–10) as well as with the 6.7%
nd 4.7% rates reported in the nonoperable and high-risk
ohorts of the PARTNER trial, respectively (1,2). Trans-
ranial Doppler studies have shown that cerebral emboli can
ccur any time during the TAVI procedure but seem to
ccur most frequently during valve prosthesis positioning
nd implantation, suggesting that the embolization of cal-
ific particles from the native valve might be 1 of the main
echanisms for cerebrovascular events during TAVI pro-
edures (29). Consistent with the results of the present
tudy, however, it has been shown that only about one-half
f the neurological events are directly related to the TAVI
Figure 5 Duration of NOAF, Anticoagulation Treatment, and Ca
Patients with new-onset atrial fibrillation (NOAF) grouped according to the duration
and cardioembolic events. TAVI  transcatheter aortic valve implantation. *p  0
rate 0%] vs. no immediate [cardioembolic rate 40%] anticoagulation therapy).rocedure, whereas the other half are late (24 h) events(1). Our results suggest that NOAF may be an important
mechanism for the late neurological events after TAVI. All
patients with a late (24 h) stroke following TAVI had at
least 1 episode of AF, compared with only 25% of the
patients who complicated with a procedural stroke. Indeed,
a plausible temporal relationship between NOAF and stroke
was found in 4 of the 5 patients with late stroke and also in
the patient who suffered a systemic embolism. Importantly,
anticoagulation treatment was not optimal in 3 of the 5
patients with late stroke, either because the episode of AF
was considered too short to start anticoagulant therapy (2
patients) or for safety reasons due to the presence of an
epidural catheter for pain relief after a transapical procedure
(1 patient). The risk of a cardioembolic event was as high as
40% in those patients who had NOAF and did not receive
anticoagulant therapy, even if AF episodes were of short
(12 h) duration. These results strongly suggest that
anticoagulation therapy should have been started immedi-
ately after diagnosis of the AF episode and continued for
several months. No clear guidelines exist on anticoagulation
therapy following short episodes of postoperative AF
(15,30). However, patients undergoing TAVI nowadays are
at high risk for thromboembolism in case of atrial arrhyth-
mia (median CHADS2 score of the study population of 3),
and a more aggressive antithrombotic treatment should
probably be implemented in these cases. Also, although the
guidelines recommend a 24-h delay for initiating anticoag-
mbolic Events
atrial fibrillation episode, anticoagulant treatment upon the diagnosis of NOAF,
r differences between short episodes of NOAF groups (immediate [cardioembolicrdioe
of the
.017 foulation in the presence of an epidural catheter (16), some
187JACC Vol. 59, No. 2, 2012 Amat-Santos et al.
January 10, 2012:178–88 TAVI and Atrial Fibrillationrecent studies have shown the safety of anticoagulant
therapy in the presence of or when removing an epidural
catheter (31,32). Finally, although double antiplatelet ther-
apy with aspirin and clopidogrel has been empirically
recommended following TAVI, future randomized studies
will have to evaluate the more appropriate antithrombotic
treatment following these procedures and the potential role
for systematic anticoagulant therapy either with warfarin or
direct thrombin inhibitors in this setting.
Study limitations. Although patients with known chronic
or paroxysmal AF were excluded from this study, and all
patients were in sinus rhythm at baseline, no electrocardio-
gram monitoring studies were performed before the TAVI
procedures to evaluate the presence of silent episodes of AF.
Although the occurrence of NOAF remained associated with
a higher rate of cardioembolic events after adjustment for
baseline differences between groups (NOAF vs. no-NOAF),
Figure 6 Survival Curves at 1-Year Follow-Up
Kaplan-Meier survival curves showing the percent of patients free of cerebrovascu
death or stroke (D) at 1-year follow-up, according to the occurrence of new-onset athe total number of events was relatively low, and this may haveled to overfitting of the multivariate model. These results must,
therefore, be confirmed by larger studies.
Conclusions
NOAF is a frequent complication associated with TAVI, with
about half of the AF episodes occurring within 24 h and80%
within the first 3 days after the procedure. Larger atrial size and
transapical approach were independent predictors of NOAF
following TAVI. The mortality rates at 30 days and at
follow-up were similar between patients with and without
NOAF. However, NOAF was associated with a higher rate of
cardioembolic events (stroke, systemic embolism) following the
procedure, especially late (24 h) events, and this provides
important new insight into the mechanisms of cerebrovascular
events following TAVI. Indeed, some cardioembolic events
seemed to be related to the no initiation of anticoagulant
nt (transient ischemic attack or stroke) (A), stroke (B), death (C), and
brillation (NOAF) following transcatheter aortic valve implantation.lar eve
trial fitherapy upon documentation of the AF episode, which further
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TAVI and Atrial Fibrillation January 10, 2012:178–88emphasizes the clinical relevance of optimizing antithrombotic
treatment in this high-risk subset of patients. It is also
important to note that these results were obtained in a TAVI
cohort made up predominantly of patients treated by transapi-
cal approach. Finally, future studies will have to determine the
potential usefulness of implementing preventive strategies to
reduce the occurrence of NOAF and its potentially devastating
consequences in the setting of TAVI.
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